In vitro transcription (IVT) is a laboratory method that uses a DNA template and an RNA polymerase enzyme to synthesize RNA—most commonly messenger RNA (mRNA)—outside of a living cell. You provide a linear DNA template containing a promoter sequence, the four ribonucleotide triphosphates (NTPs), and a reaction buffer, and the enzyme produces a single-stranded RNA copy that can be capped, tailed, and purified for research or therapeutic use. This article explains the core steps, the components you need, common pitfalls, and how the process is used in real-world applications like vaccines and gene therapy.
Formula
The calculator estimates the total mass of RNA produced and the molar amount (in picomoles) based on the mass of DNA template, the template length, and an expected yield factor.
- Total RNA yield (µg) = mass of DNA template (µg) × expected yield (µg RNA per µg DNA)
- RNA amount (pmol) = (total RNA yield in µg × 106) / (template length in kb × 1000 × 340 g/mol per base)
Variables:
- m – mass of linear DNA template in micrograms (µg). Typical IVT reactions use 0.5–2 µg of template.
- l – length of the DNA template in kilobases (kb). For an mRNA of 2 kb, the template is about 2 kb (excluding promoter and UTRs).
- y – expected yield in µg of RNA per µg of DNA template. This varies widely with polymerase and reaction conditions; 10 µg/µg is a reasonable average for T7 RNA polymerase with optimized NTP concentrations.
- 340 g/mol – average molecular weight of a ribonucleotide monophosphate in the RNA chain (the free acid form). This is a standard approximation.
Worked Example
Suppose you start with 1 µg of a 2 kb linear DNA template and expect a yield of 10 µg RNA per µg DNA.
Step 1: Calculate total RNA yield.
Total RNA yield = 1 µg × 10 = 10 µg.
Step 2: Convert µg to picomoles.
First, find the molecular weight of the RNA transcript. For a 2 kb RNA (2000 bases), MW ≈ 2000 × 340 = 680,000 g/mol.
Now convert mass to moles:
10 µg = 10 × 10-6 g.
Moles = (10 × 10-6 g) / (680,000 g/mol) = 1.4706 × 10-11 mol.
Picomoles = 1.4706 × 10-11 mol × 1012 pmol/mol = 14.7 pmol.
The calculator gives the same result: 10 µg and 14.7 pmol.
Assumptions
- The DNA template is linear and contains a functional promoter recognized by the RNA polymerase (e.g., T7, T3, SP6).
- The template is pure and free of RNase contamination.
- The yield factor is an average; actual yields depend on NTP concentration, incubation time, temperature, and the specific polymerase.
- The average molecular weight per ribonucleotide is taken as 340 g/mol (free acid form). This is an approximation; the exact value depends on sequence.
Background: Why In Vitro Transcription?
In vitro transcription was developed in the 1980s as a tool to produce RNA probes for hybridization studies. The key breakthrough was the use of bacteriophage RNA polymerases—T7, T3, and SP6—that are highly processive and require only a short promoter sequence. Unlike bacterial RNA polymerase, these single-subunit enzymes are simple to use and produce large amounts of RNA from a small DNA template.
The technique became a cornerstone of molecular biology, enabling the synthesis of labeled RNA probes, the production of RNA for structural studies, and more recently, the manufacturing of mRNA vaccines. The COVID-19 mRNA vaccines brought IVT into the public spotlight, but the same chemistry is used to produce RNA for gene therapy, cell reprogramming, and RNA-based therapeutics.
How In Vitro Transcription Works
The process can be broken into five main stages:
- Template preparation: You need a linear DNA template that contains a promoter upstream of the sequence to be transcribed. The template is typically generated by PCR or by linearizing a plasmid with a restriction enzyme. The DNA must be linear because circular DNA causes run-on transcripts and poor termination.
- Assembly: The reaction is assembled in a tube with the DNA template, RNA polymerase, NTPs (ATP, CTP, GTP, UTP), a buffer containing magnesium ions (Mg2+), and a reducing agent like DTT. Optionally, you add RNase inhibitor and pyrophosphatase to improve yield.
- Incubation: The reaction is incubated at 37 °C (for T7 polymerase) for 1–4 hours. During this time, the polymerase binds the promoter, unwinds the DNA, and synthesizes RNA in the 5′ to 3′ direction.
- DNase treatment: After incubation, DNase I is added to degrade the DNA template, leaving only the RNA product.
- Purification: The RNA is purified by precipitation (e.g., lithium chloride) or column chromatography to remove enzymes, NTPs, and salts.
For mRNA therapeutics, additional steps include adding a 5′ cap (either co-transcriptionally with cap analogs or post-transcriptionally with capping enzymes) and a 3′ poly(A) tail. These modifications are essential for mRNA stability and translation in cells.
Choosing the Right Polymerase and Template
The most common polymerases are T7, T3, and SP6. They are similar, but each recognizes a different promoter sequence. T7 is the most widely used because it is highly processive and produces high yields. Your choice of polymerase depends on the promoter sequence available in your template.
Template design matters greatly. For mRNA production, the template should include:
- A 5′ untranslated region (UTR) that promotes ribosome binding.
- The coding sequence (open reading frame) for your protein.
- A 3′ UTR and a poly(A) tail (often encoded in the template as a run of T’s).
- A restriction site for linearization at the end, so the polymerase runs off and stops.
If you are making short RNA probes (<200 nt), you can use a template with a defined end. For longer mRNAs, ensure the template is free of nicks and RNase contamination.
Common Problems and How to Fix Them
IVT is generally robust, but several issues can reduce yield or quality:
- Low yield: Often due to insufficient NTPs, too little template, or inactive polymerase. Increase NTP concentration (up to 7.5 mM each) or extend incubation time.
- RNA degradation: RNases are everywhere. Use RNase-free water, wear gloves, and include an RNase inhibitor in the reaction.
- Abortive transcripts: Short, incomplete RNA products can appear. They are usually removed during purification.
- Precipitation of DNA template: If the template is too concentrated or contains salts, it may precipitate. Use a clean linearization and purify the DNA before IVT.
- Double-stranded RNA (dsRNA) byproducts: These can trigger innate immune responses in cells. They are formed by RNA-dependent RNA polymerase activity or by template-independent extension. Use a high-yield polymerase and purify with methods that remove dsRNA (e.g., cellulose chromatography).
A common misconception is that you need a cap analog in the reaction to get a functional mRNA. While cap analogs are used in many protocols, you can also add the cap later using a capping enzyme. The choice depends on your downstream application.
Costs and Alternatives
The cost of an IVT reaction depends on the scale and the modifications you need. A standard lab-scale reaction (20 µL) with commercial kits costs roughly $20–$50 in reagents. For large-scale GMP production (as for vaccines), costs are higher due to purification and quality control.
Alternatives to IVT for producing RNA include:
- Chemical synthesis: Suitable for short RNAs (<100 nt), but impractical for long mRNAs.
- Cell-based expression: You can express RNA in bacteria or yeast, but they often degrade or modify it differently.
- Self-amplifying RNA: A modified mRNA that encodes its own replicase, allowing a smaller initial dose. This still relies on IVT for production.
For most research and therapeutic applications, IVT remains the method of choice because it is fast, scalable, and produces RNA with defined sequence and modifications.
Safety and Best Practices
When performing IVT, follow your lab’s safety guidelines and the SDS for all reagents. Key points:
- Wear gloves and use RNase-free techniques to avoid contamination.
- Handle NTPs and cap analogs with care; they are generally non-toxic but can be irritating.
- Use a dedicated RNase-free work area or treat surfaces with RNase decontamination solutions.
- Dispose of DNase and other enzymes according to your institution’s waste rules.
Always verify your RNA product by gel electrophoresis or Bioanalyzer to check size and integrity. For functional studies, a translation assay (e.g., in vitro translation or cell transfection) confirms the mRNA is active.
Frequently Asked Questions
What is the difference between in vitro transcription and reverse transcription?
In vitro transcription synthesizes RNA from a DNA template using RNA polymerase. Reverse transcription is the opposite: it synthesizes DNA from an RNA template using reverse transcriptase. IVT is used to make RNA probes or mRNA, while reverse transcription is used to make cDNA for cloning or qPCR.
Can I use plasmid DNA directly in IVT?
Yes, but the plasmid must be linearized first, typically by restriction enzyme digestion at a site downstream of the insert. Circular plasmid DNA leads to long, heterogeneous transcripts because the polymerase does not stop efficiently. After linearization, purify the DNA to remove enzymes and salts.
How do I add a 5′ cap to my mRNA?
There are two main ways: co-transcriptional capping uses a cap analog (e.g., m7GpppG) in the IVT reaction, which is incorporated at the 5′ end. Alternatively, you can add the cap post-transcriptionally using a capping enzyme (e.g., vaccinia capping enzyme) that adds a guanine cap in a separate reaction. Co-transcriptional capping is simpler but often yields a lower percentage of capped RNA; post-transcriptional capping gives more uniform capping.
Why is my RNA yield lower than expected?
Common reasons include: insufficient NTPs (they get depleted), too little template, inactive polymerase (freeze-thaw cycles), or RNase contamination. Check the concentration of your template by spectrophotometry, use fresh NTPs, and include an RNase inhibitor. Also, ensure the incubation time is adequate—some templates need 4 hours for maximal yield.
Is in vitro transcription used to make mRNA vaccines?
Yes, mRNA vaccines (such as those for COVID-19) are produced using large-scale in vitro transcription. The process is similar to lab-scale IVT but is optimized for GMP compliance, including rigorous purification to remove dsRNA and other impurities. The resulting mRNA is formulated into lipid nanoparticles for delivery.
What is the typical size of mRNA produced by IVT?
mRNA for therapeutic use is typically 1,000 to 5,000 nucleotides long. The IVT reaction can produce RNA up to 10 kb or more, but longer transcripts become less efficient and more prone to degradation. For very long mRNAs, consider optimizing the reaction with higher NTP concentrations and lower temperature.
Related
Formula used
in m | Mass of DNA template | µg | 1 | 0 in l | DNA template length | kb | 2 | 0.1 in y | Expected yield per µg template | µg RNA/µg DNA | 10 | 0 out r | Total RNA yield | µg | m * y | 2 out pmol | RNA amount (pmol) | pmol | (r * 1e6) / (l * 1000 * 340) | 2
Each line is one input (in, sel, list) or one result (out: label, unit, formula, decimals). How the calculators work
Method: the standard formula for this calculation with the constants and conversion factors written on the page, rounded as each result states. See method and constants, the disclaimer or report an error.
More in this section
- Normality to meq/mL Conversion Calculator1.0000 meq/mL
- Normality to g/L Converter & Formula29.220 g/L
- Normality Test Q-Q Plot: How to Read It
- Normality Test Results: How to Analyze Them
- Normality Slay the Spire?
- Normality Test for Paired t Test: How to Check